Omalizumab for the management of refractory aquagenic pruritus.

Koumaki, D; Gregoriou, S; Katoulis, A; Evangelou, G

Koumaki, D; Gregoriou, S; Katoulis, A; Evangelou, G.

Afiliación

Koumaki D; Dermatology Department, University Hospital of Heraklion, Heraklion, Greece.
Gregoriou S; Department of Dermatology and Venereology, Andreas Sygros Hospital, Medical School of Athens, National and Kapodistrian University of Athens, Athens, Greece.
Katoulis A; 2nd Department of Dermatology and Venereology, Medical School, "Attikon" General University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Evangelou G; Dermatology Department, University Hospital of Heraklion, Heraklion, Greece.

J Eur Acad Dermatol Venereol ; 37(11): e1316-e1317, 2023 11.

Article en En | MEDLINE | ID: mdl-37415343

Asunto(s)

Omalizumab; Prurito; Humanos; Omalizumab/uso terapéutico; Prurito/tratamiento farmacológico; Prurito/etiología; Agua/efectos adversos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Prurito / Omalizumab Límite: Humans Idioma: En Revista: J Eur Acad Dermatol Venereol Asunto de la revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: Grecia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google